Arbutus Biopharma Corp (ABUS) — Financial statements
Income statement, balance sheet, and cash flow for Arbutus Biopharma Corp — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 14↑128.2% | 6↓66.0% | 18↓53.5% | 39↑255.1% | 11 | |
| Cost of Revenue | 0.36 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 14↑122.3% | 6↓66.0% | 18↓53.5% | 39↑255.1% | 11 | |
| Operating Expenses | ||||||
| R&D Expenses | 25↓53.3% | 54↓26.7% | 74↓12.7% | 84↑28.9% | 66 | |
| General & Administrative Expenses | 16↓28.1% | 22↓1.6% | 22↑26.0% | 18↑4.1% | 17 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 16↓28.1% | 22↓1.6% | 22↑26.0% | 18↑4.1% | 17 | |
| Other Expenses | -0.36↓105.7% | 6↑9095.7% | 0.07↓96.9% | 2↑19.3% | 2 | |
| Operating Expenses | 41↓50.6% | 82↓14.3% | 96↓7.9% | 104↑23.6% | 85 | |
| Total Costs & Expenses | 41↓50.1% | 82↓14.3% | 96↓7.9% | 104↑23.6% | 85 | |
| Operating Results | ||||||
| Operating Income | -27↑64.6% | -76↑2.3% | -78↓19.3% | -65↑11.0% | -74 | |
| Depreciation & Amortization | 0.36↓73.7% | 1↓1.7% | 1↓1.6% | 1↓18.6% | 2 | |
| EBITDA | -27↑61.0% | -68↑3.6% | -71↓14.8% | -62↑13.6% | -72 | |
| EBIT | -27↑61.2% | -70↑3.6% | -72↓14.4% | -63↑13.8% | -73 | |
| Interest & Other Income | ||||||
| Net Interest Income | 4↓38.4% | 6↑23.3% | 5↑1022.1% | 0.47↑117.1% | -3 | |
| Interest Income | 4↓38.2% | 7↑15.8% | 6↑159.5% | 2↑1626.0% | 0.13 | |
| Interest Expense | 0.10↓29.2% | 0.14↓70.2% | 0.46↓73.4% | 2↓39.6% | 3 | |
| Non-Operating Income | 0.00↑100.0% | -7↓14.4% | -6↓163.3% | -2↓1543.9% | -0.13 | |
| Other Income / Expenses | -6↓200.8% | 6↑21.8% | 5↑1083.3% | 0.44↑116.3% | -3 | |
| Income Before Tax | -34↑52.1% | -70↑4.0% | -73↓12.1% | -65↑14.7% | -76 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00↓100.0% | 4 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -34↑52.1% | -70↑4.0% | -73↓4.9% | -69↑8.9% | -76 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -34↑52.1% | -70↑4.0% | -73↓4.9% | -69↑8.9% | -76 | |
| Bottom-Line Net Income | -34↑52.1% | -70↑4.0% | -73↓4.9% | -69↑21.4% | -88 | |
| EPS (Basic) | -0.17↑55.3% | -0.38↑13.6% | -0.44↑4.3% | -0.46↑37.0% | -0.73 | |
| EPS (Diluted) | -0.17↑55.3% | -0.38↑13.6% | -0.44↑4.3% | -0.46↑37.0% | -0.73 | |
| Weighted Average Shares | 192↑3.2% | 186↑11.8% | 166↑10.0% | 151↑42.1% | 106 | |
| Weighted Average Diluted Shares | 192↑3.2% | 186↑11.8% | 166↑10.0% | 151↑42.1% | 106 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.